Adeniyi Olagunju1, Oluseye Bolaji2, Alieu Amara3, Catriona Waitt4, Laura Else3, Ebunoluwa Adejuyigbe5, Marco Siccardi4, David Back4, Saye Khoo4, Andrew Owen4. 1. Department of Molecular and Clinical Pharmacology, University of Liverpool, United Kingdom Faculty of Pharmacy, Obafemi Awolowo University, Ile-Ife, Nigeria. 2. Faculty of Pharmacy, Obafemi Awolowo University, Ile-Ife, Nigeria. 3. Liverpool Bioanalytical Facility, Department of Molecular and Clinical Pharmacology, University of Liverpool, United Kingdom. 4. Department of Molecular and Clinical Pharmacology, University of Liverpool, United Kingdom. 5. Department of Paediatrics and Child Health, Obafemi Awolowo University, Ile-Ife, Nigeria.
Abstract
BACKGROUND: The antiretroviral drug efavirenz is widely used during breastfeeding. Evaluating its safety requires an understanding of its breast milk pharmacokinetics, level of breastfed infants' exposure, and potential influence of polymorphisms in drug disposition genes. METHODS: For this observational study, we investigated plasma and breast milk pharmacokinetics of efavirenz and breastfed infants' exposure in human immunodeficiency virus positive nursing mothers and their breastfed infants. We also evaluated potential variability due to genetic polymorphisms in CYP2B6, NR1I3, CYP2A6, ABCB1, ABCB5, and ABCG2. RESULTS: CYP2B6 516G>T was independently associated with efavirenz concentrations in maternal plasma, breast milk, and infant plasma (n = 134). When stratified based on CYP2B6 516G>T (n = 29 ; 11 GG, 10 GT and 8 TT), efavirenz pharmacokinetic parameters in plasma and breast milk differed significantly between patient groups. The median time-averaged milk-to-plasma concentration ratio was 1.10 (range: 0.57-1.71). The estimated maximum infant efavirenz dose from breast milk was 809 µg/kg/day (215-2760) and pediatric dose weight-adjusted exposure index was 4.05% (1.08-13.8). Infant plasma concentrations did not change significantly during the dosing interval, 157 ng/mL (28.6-1360) in pooled analysis and 315 ng/mL (108-1360) in CYP2B6 516TT group. Infant plasma concentrations were highest up to 8 days of age at 1590 ng/mL (190-4631) and decreased by about 90% in the age stratum day 9 to 3 months. No efavirenz related toxicity was reported. CONCLUSIONS: Most breastfed infants are exposed to <10% of the weight-adjusted therapeutic pediatric dose, the safety threshold for exposure to maternal drugs from breast milk.
BACKGROUND: The antiretroviral drug efavirenz is widely used during breastfeeding. Evaluating its safety requires an understanding of its breast milk pharmacokinetics, level of breastfed infants' exposure, and potential influence of polymorphisms in drug disposition genes. METHODS: For this observational study, we investigated plasma and breast milk pharmacokinetics of efavirenz and breastfed infants' exposure in human immunodeficiency virus positive nursing mothers and their breastfed infants. We also evaluated potential variability due to genetic polymorphisms in CYP2B6, NR1I3, CYP2A6, ABCB1, ABCB5, and ABCG2. RESULTS: CYP2B6 516G>T was independently associated with efavirenz concentrations in maternal plasma, breast milk, and infant plasma (n = 134). When stratified based on CYP2B6 516G>T (n = 29 ; 11 GG, 10 GT and 8 TT), efavirenz pharmacokinetic parameters in plasma and breast milk differed significantly between patient groups. The median time-averaged milk-to-plasma concentration ratio was 1.10 (range: 0.57-1.71). The estimated maximum infant efavirenz dose from breast milk was 809 µg/kg/day (215-2760) and pediatric dose weight-adjusted exposure index was 4.05% (1.08-13.8). Infant plasma concentrations did not change significantly during the dosing interval, 157 ng/mL (28.6-1360) in pooled analysis and 315 ng/mL (108-1360) in CYP2B6 516TT group. Infant plasma concentrations were highest up to 8 days of age at 1590 ng/mL (190-4631) and decreased by about 90% in the age stratum day 9 to 3 months. No efavirenz related toxicity was reported. CONCLUSIONS: Most breastfed infants are exposed to <10% of the weight-adjusted therapeutic pediatric dose, the safety threshold for exposure to maternal drugs from breast milk.
Authors: George Kafulafula; Donald R Hoover; Taha E Taha; Michael Thigpen; Qing Li; Mary Glenn Fowler; Newton I Kumwenda; Kondwani Nkanaunena; Linda Mipando; Lynne M Mofenson Journal: J Acquir Immune Defic Syndr Date: 2010-01 Impact factor: 3.731
Authors: Rob ter Heine; Henriette J Scherpbier; Kristel M L Crommentuyn; Vincent Bekker; Jos H Beijnen; Taco W Kuijpers; Alwin D R Huitema Journal: Antivir Ther Date: 2008
Authors: N T Parkin; N S Hellmann; J M Whitcomb; L Kiss; C Chappey; C J Petropoulos Journal: Antimicrob Agents Chemother Date: 2004-02 Impact factor: 5.191
Authors: Edward L Croom; Jeffrey C Stevens; Ronald N Hines; Andrew D Wallace; Ernest Hodgson Journal: Biochem Pharmacol Date: 2009-04-05 Impact factor: 5.858
Authors: Regis Kreitchmann; Stein Schalkwijk; Brookie Best; Jiajia Wang; Angela Colbers; Alice Stek; David Shapiro; Tim Cressey; Mark Mirochnick; David Burger Journal: Antivir Ther Date: 2019
Authors: Upal Roy; Hong Ding; Sudheesh Pilakka-Kanthikeel; Andrea D Raymond; Venkata Atluri; Adriana Yndart; Elena M Kaftanovskaya; Elena Batrakova; Marisela Agudelo; Madhavan Nair Journal: Int J Nanomedicine Date: 2015-09-18
Authors: Ahmad Haeri Mazanderani; Tanya Y Murray; Gayle G Sherman; Tracy Snyman; Jaya George; Theunis Avenant; Ameena E Goga; Michael S Pepper; Nicolette du Plessis Journal: J Int AIDS Soc Date: 2019-06 Impact factor: 5.396
Authors: Ahizechukwu C Eke; Adeniyi Olagunju; Jeremiah Momper; Martina Penazzato; Elaine J Abrams; Brookie M Best; Edmund V Capparelli; Adrie Bekker; Yodit Belew; Jennifer J Kiser; Kimberly Struble; Graham Taylor; Catriona Waitt; Mark Mirochnick; Tim R Cressey; Angela Colbers Journal: Clin Pharmacol Ther Date: 2020-10-15 Impact factor: 6.875